{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:09:18Z","timestamp":1790762958733,"version":"4.1.0"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Disulfiram and hydralazine have recently been reported to have anti-cancer action, and repositioned to be used as adjuvant in cancer therapy. Chemotherapy combined with other medications, such as those that affect the immune system or epigenetic cell profile, can overcome resistance with fewer adverse effects compared to chemotherapy alone. In the present study, a combination of doxorubicin (DOX) with hydrazine (Hyd) and disulfiram (Dis), as a triple treatment, was evaluated against wild-type and DOX-resistant MCF-7 breast cancer cell line. Both wild-type MCF-7 cell line (MCF-7_WT) and DOX-resistant MCF-7 cell line (MCF-7_DoxR) were treated with different combination ratios of DOX, Dis, and Hyd followed by measuring the cell viability using the MTT assay. Synergism was determined using a combination index, isobologram analysis, and dose-reducing index. The anti-proliferation activity and mechanism of the triple combination were investigated by apoptosis analysis. The results showed a reduction in the IC<jats:sub>50<\/jats:sub> values of DOX in MCF-7_WT cells (from 0.24 \u03bcM to 0.012 \u03bcM) and MCF-7_DoxR cells (from 1.13 \u03bcM to 0.44 \u03bcM) when treated with Dis (0.03\u03bcM), and Hyd (20\u03bcM) combination. Moreover, The triple combination DOX\/Hyd\/Dis induced significant apoptosis in both MCF-7_WT and MCF-7_DoxR cells compared to DOX alone. The triple combination of DOX, Dis, and Hyd showed a synergistic drugs combination to decrease the DOX dose needed to kill both MCF-7_WT and MCF-7_DoxR cancer cells and enhanced chemosensitivity to DOX.<\/jats:p>","DOI":"10.1371\/journal.pone.0291981","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:39:18Z","timestamp":1695922758000},"page":"e0291981","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line"],"prefix":"10.1371","volume":"18","author":[{"given":"Zainab","family":"Lafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-7328","authenticated-orcid":true,"given":"Walhan","family":"Alshaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobna","family":"Gharaibeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana A.","family":"Alqudah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baidaa","family":"AlQuaissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banan","family":"Bashaireh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed Alqader","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"issue":"3","key":"pone.0291981.ref001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"H Sung","year":"2021","journal-title":"CA: a cancer journal for clinicians"},{"issue":"3","key":"pone.0291981.ref002","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"AG Waks","year":"2019","journal-title":"Jama"},{"issue":"1","key":"pone.0291981.ref003","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/cancers12010162","article-title":"Improvement in the anti-tumor efficacy of doxorubicin nanosponges in in vitro and in mice bearing breast tumor models","volume":"12","author":"M Argenziano","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"pone.0291981.ref004","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdn728","article-title":"Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk","volume":"20","author":"P Barrett-Lee","year":"2009","journal-title":"Annals of oncology"},{"issue":"11","key":"pone.0291981.ref005","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"S Zhang","year":"2012","journal-title":"Nature medicine"},{"issue":"2","key":"pone.0291981.ref006","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"X Wang","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"pone.0291981.ref007","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/978-1-60761-416-6_21","article-title":"Circumventing tumor resistance to chemotherapy by nanotechnology","volume":"596","author":"XJ Liang","year":"2010","journal-title":"Methods Mol Biol"},{"key":"pone.0291981.ref008","doi-asserted-by":"crossref","first-page":"137414","DOI":"10.1155\/2013\/137414","article-title":"Drug resistance and the role of combination chemotherapy in improving patient outcomes","volume":"2013","author":"DA Yardley","year":"2013","journal-title":"Int J Breast Cancer"},{"issue":"19","key":"pone.0291981.ref009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194783","article-title":"New Strategies to Overcome Resistance to Chemotherapy and Immune System in Cancer.","volume":"20","author":"C Riganti","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"pone.0291981.ref010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1513\/pats.200504-037SR","article-title":"Pharmacologic principles for combination therapy","volume":"2","author":"ML Toews","year":"2005","journal-title":"Proc Am Thorac Soc"},{"issue":"9","key":"pone.0291981.ref011","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic Determinants of Cancer.","volume":"8","author":"SB Baylin","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"23","key":"pone.0291981.ref012","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"R Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"issue":"6990","key":"pone.0291981.ref013","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"G Egger","year":"2004","journal-title":"Nature"},{"key":"pone.0291981.ref014","doi-asserted-by":"crossref","first-page":"605386","DOI":"10.3389\/fonc.2020.605386","article-title":"Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy.","volume":"10","author":"M Montalvo-Casimiro","year":"2020","journal-title":"Front Oncol"},{"issue":"9","key":"pone.0291981.ref015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22095047","article-title":"Epigenetics, microRNA and Metabolic Syndrome: A Comprehensive Review.","volume":"22","author":"F Ramzan","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0291981.ref016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13148-019-0776-0","article-title":"The timeline of epigenetic drug discovery: from reality to dreams","volume":"11","author":"A Ganesan","year":"2019","journal-title":"Clin Epigenetics"},{"issue":"1","key":"pone.0291981.ref017","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1038\/s41598-020-60409-4","article-title":"Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer","volume":"10","author":"S Moufarrij","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0291981.ref018","first-page":"1","article-title":"Using Epigenetic Therapy to Overcome Chemotherapy Resistance","volume":"36","author":"J Strauss","year":"2016","journal-title":"Anticancer Res"},{"issue":"1","key":"pone.0291981.ref019","first-page":"113","article-title":"Epigenetic basis of cancer drug resistance","volume":"3","author":"MH Aziz","year":"2020","journal-title":"Cancer Drug Resist"},{"key":"pone.0291981.ref020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-4-10","article-title":"Hydralazine target: from blood vessels to the epigenome","volume":"4","author":"C Arce","year":"2006","journal-title":"J Transl Med"},{"issue":"1","key":"pone.0291981.ref021","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13046-019-1160-9","article-title":"Valproic acid exhibits anti-tumor activity selectively against EGFR\/ErbB2\/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs","volume":"38","author":"T Lin","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"pone.0291981.ref022","doi-asserted-by":"crossref","first-page":"645518","DOI":"10.3389\/fcell.2021.645518","article-title":"Sodium Valproate-Induced Chromatin Remodeling.","volume":"9","author":"MLS Mello","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"pone.0291981.ref023","doi-asserted-by":"crossref","first-page":"e0265497","DOI":"10.1371\/journal.pone.0265497","article-title":"Blood pressure response to commonly administered antihypertensives for severe inpatient hypertension","volume":"17","author":"L Ghazi","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"pone.0291981.ref024","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1038\/emm.2017.38","article-title":"Methylation and demethylation of DNA and histones in chromatin: the most complicated epigenetic marker","volume":"49","author":"HD Youn","year":"2017","journal-title":"Exp Mol Med"},{"key":"pone.0291981.ref025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-4-32","article-title":"Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine","volume":"4","author":"B Segura-Pacheco","year":"2006","journal-title":"J Transl Med"},{"key":"pone.0291981.ref026","article-title":"Aldehyde Dehydrogenase: Cancer and Stem Cells.","author":"A M","year":"2012","journal-title":"Dehydrogenases"},{"issue":"24","key":"pone.0291981.ref027","doi-asserted-by":"crossref","first-page":"518","DOI":"10.21037\/atm.2016.11.82","article-title":"Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets","volume":"4","author":"DW Clark","year":"2016","journal-title":"Ann Transl Med"},{"issue":"2","key":"pone.0291981.ref028","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"MD Skinner","year":"2014","journal-title":"PloS one"},{"issue":"6","key":"pone.0291981.ref029","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.drudis.2020.04.003","article-title":"The combination of disulfiram and copper for cancer treatment","volume":"25","author":"H Li","year":"2020","journal-title":"Drug Discovery Today"},{"issue":"11","key":"pone.0291981.ref030","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2174\/1871520615666160504095040","article-title":"Disulfiram\u2019s Anticancer Activity: Evidence and Mechanisms.","volume":"16","author":"Y Jiao","year":"2016","journal-title":"Anticancer Agents Med Chem"},{"issue":"10","key":"pone.0291981.ref031","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.tips.2019.08.002","article-title":"Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics","volume":"40","author":"SS Dinavahi","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"pone.0291981.ref032","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2020.00265","article-title":"Perplexing role of P-glycoprotein in tumor microenvironment","volume":"10","author":"K Robinson","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"pone.0291981.ref033","doi-asserted-by":"crossref","first-page":"119191","DOI":"10.1016\/j.ijpharm.2020.119191","article-title":"Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells","volume":"580","author":"F Rolle","year":"2020","journal-title":"Int J Pharm"},{"issue":"15","key":"pone.0291981.ref034","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.3390\/ijms20153696","article-title":"Downregulation of STAT3, \u03b2-catenin, and notch-1 by single and combinations of siRNA treatment enhance chemosensitivity of wild type and doxorubicin resistant MCF7 breast cancer cells to doxorubicin","volume":"20","author":"W Alshaer","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"D1","key":"pone.0291981.ref035","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"D Szklarczyk","year":"2023","journal-title":"Nucleic Acids Research"},{"issue":"2","key":"pone.0291981.ref036","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: The bright side of the moon.","volume":"52","author":"B Perillo","year":"2020","journal-title":"Experimental & molecular medicine"},{"issue":"1","key":"pone.0291981.ref037","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Z Chen","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"7","key":"pone.0291981.ref038","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/bjc.2013.534","article-title":"Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells","volume":"109","author":"P Liu","year":"2013","journal-title":"Br J Cancer"},{"issue":"5","key":"pone.0291981.ref039","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.3892\/or.2017.5972","article-title":"DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review).","volume":"38","author":"M Nowacka-Zawisza","year":"2017","journal-title":"Oncol Rep"},{"key":"pone.0291981.ref040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2121-12-2","article-title":"Drug-induced cell cycle modulation leading to cell-cycle arrest, nuclear mis-segregation, or endoreplication","volume":"12","author":"A Sakaue-Sawano","year":"2011","journal-title":"BMC Cell Biol"},{"key":"pone.0291981.ref041","doi-asserted-by":"crossref","first-page":"1072651","DOI":"10.3389\/fphar.2022.1072651","article-title":"Recent progress in DNA methyltransferase inhibitors as anticancer agents","volume":"13","author":"Z Zhang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"pone.0291981.ref042","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1042\/BCJ20180440","article-title":"lncRedibly versatile: biochemical and biological functions of long noncoding RNAs","volume":"476","author":"EJ Shields","year":"2019","journal-title":"Biochemical Journal"},{"issue":"16","key":"pone.0291981.ref043","doi-asserted-by":"crossref","first-page":"21875","DOI":"10.18632\/oncotarget.7871","article-title":"The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells","volume":"7","author":"MJ Ruiz-Maga\u00f1a","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"pone.0291981.ref044","first-page":"197","article-title":"Disulfiram induces apoptosis in human melanoma cells: a redox-related process","volume":"1","author":"D Cen","year":"2002","journal-title":"Molecular cancer therapeutics"},{"key":"pone.0291981.ref045","doi-asserted-by":"crossref","first-page":"102122","DOI":"10.1016\/j.redox.2021.102122","article-title":"Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram\/copper-induced ferroptosis","volume":"46","author":"X Ren","year":"2021","journal-title":"Redox Biology"},{"key":"pone.0291981.ref046","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.biopha.2016.06.051","article-title":"Up-regulation of glutathione-related genes, enzyme activities and transport proteins in human cervical cancer cells treated with doxorubicin","volume":"83","author":"E Drozd","year":"2016","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"issue":"38","key":"pone.0291981.ref047","doi-asserted-by":"crossref","first-page":"40907","DOI":"10.18632\/oncotarget.5723","article-title":"Disulfiram inhibits TGF-\u03b2-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK\/NF-\u03baB\/Snail pathway","volume":"6","author":"D Han","year":"2015","journal-title":"Oncotarget"},{"key":"pone.0291981.ref048","doi-asserted-by":"crossref","first-page":"110048","DOI":"10.1016\/j.biopha.2020.110048","article-title":"Disulfiram\/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways.","volume":"126","author":"Y Xu","year":"2020","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"pone.0291981.ref049","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fphar.2013.00089","article-title":"Mechanisms regulating resistance to inhibitors of topoisomerase II.","volume":"4","author":"RN Ganapathi","year":"2013","journal-title":"Front Pharmacol"},{"key":"pone.0291981.ref050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"M Arnold","year":"2022","journal-title":"Breast"},{"issue":"9","key":"pone.0291981.ref051","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of Multidrug Resistance in Cancer Chemotherapy","volume":"21","author":"K Bukowski","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"pone.0291981.ref052","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1535-7163.MCT-06-0663","article-title":"Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets","volume":"6","author":"VF Chekhun","year":"2007","journal-title":"Molecular cancer therapeutics"},{"issue":"12","key":"pone.0291981.ref053","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1039\/D0BM00062K","article-title":"Disulfiram-gold-nanorod integrate for effective tumor targeting and photothermal-chemical synergistic therapy","volume":"8","author":"C Xu","year":"2020","journal-title":"Biomaterials science"},{"issue":"4","key":"pone.0291981.ref054","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0092-8674(94)90518-5","article-title":"Apoptosis in cancer therapy: crossing the threshold","volume":"78","author":"DE Fisher","year":"1994","journal-title":"Cell"},{"issue":"2","key":"pone.0291981.ref055","first-page":"297","article-title":"Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer","volume":"2","author":"L Ponnusamy","year":"2019","journal-title":"Cancer Drug Resistance"},{"key":"pone.0291981.ref056","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13578-019-0312-0","article-title":"Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3\/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells","volume":"9","author":"H Li","year":"2019","journal-title":"Cell Biosci"},{"issue":"12","key":"pone.0291981.ref057","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120483","article-title":"Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy.","volume":"10","author":"M Leary","year":"2018","journal-title":"Cancers (Basel)."},{"key":"pone.0291981.ref058","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-981-10-6020-5_4","article-title":"Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer","volume":"1026","author":"KH Chun","year":"2017","journal-title":"Advances in experimental medicine and biology"},{"key":"pone.0291981.ref059","first-page":"2581","article-title":"Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention, and Therapeutic Approaches.","author":"TB Emran","year":"2022","journal-title":"Frontiers in Oncology."},{"issue":"1","key":"pone.0291981.ref060","doi-asserted-by":"crossref","first-page":"22847","DOI":"10.1038\/srep22847","article-title":"Overcoming doxorubicin resistance of cancer cells by Cas9-mediated gene disruption.","volume":"6","author":"JS Ha","year":"2016","journal-title":"Scientific Reports"},{"key":"pone.0291981.ref061","doi-asserted-by":"crossref","first-page":"188866","DOI":"10.1016\/j.bbcan.2023.188866","article-title":"Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy","author":"J Ye","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA)-Reviews on Cancer."},{"issue":"9","key":"pone.0291981.ref062","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/md17090536","article-title":"Synergistic cytotoxicity of renieramycin M and doxorubicin in MCF-7 breast cancer cells","volume":"17","author":"JO Tun","year":"2019","journal-title":"Marine drugs"},{"issue":"18","key":"pone.0291981.ref063","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.4161\/cc.26063","article-title":"High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors","volume":"12","author":"TJ Robinson","year":"2013","journal-title":"Cell cycle (Georgetown, Tex)."},{"issue":"1","key":"pone.0291981.ref064","first-page":"19","article-title":"A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma.","volume":"18","author":"Y-C Liu","year":"2022"},{"issue":"9","key":"pone.0291981.ref065","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","article-title":"A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors","volume":"18","author":"M Candelaria","year":"2007","journal-title":"Annals of Oncology"},{"issue":"1","key":"pone.0291981.ref066","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1371\/journal.pone.0000098","article-title":"A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer","volume":"1","author":"C Arce","year":"2006","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:40:07Z","timestamp":1695922807000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291981"}},"subtitle":[],"editor":[{"given":"Vino","family":"Cheriyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0291981","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}